The Federal Biomedical Agency (FMBA) of Russia has received national registration for a new drug for the treatment of prostate cancer, developed by FMBA specialists.
 |
| Russian prostate cancer drug called Rakurs. (Source: UzDaily) |
A new radiopharmaceutical called "Rakurs (223Ra)" has been registered in Russia. The drug is used in radiotherapy for prostate cancer patients with bone metastases.
“Rakurs” is a dual-action drug. First, it destroys bone metastases, prolonging the life of patients in the late stages. The drug selectively accumulates in bones, including metastatic bones, providing a high local anti-cancer effect.
Second, the radioactive nucleus radium-223 significantly cuts or reduces pain, allowing patients to abandon strong painkillers and improve their quality of life. The drug's unique feature is that it selectively accumulates in bone tissue and destroys metastases without causing strong effects on healthy tissue.
Radionuclide [223Ra] is supplied by the Research Center “Research Institute of Nuclear Reactors” - Russia's largest nuclear energy research and testing complex, part of the Rosatom State Corporation.
This innovative product was developed at the Federal Scientific and Clinical Center of Radiology and Oncology (FSCCMRO) of the FMBA in Dimitrovgrad, in cooperation with specialists from the Research Institute of Atomic Reactors (JSC RIAR) - a research department of the Rosatom State Corporation.
The authors say the drug could one day be used to treat metastatic bone lesions and other cancers.
“For our team, this is another important achievement in the field of nuclear medicine. In close cooperation with colleagues from FSCCMRO, we have developed a drug with great potential. Each stage of this collaborative effort required innovative solutions and a combination of solid scientific ideas and rigorous implementation. We are on the right track and our partnership will continue to develop,” said Alexander Tuzov, Director of JSC RIAR.
Registration of this innovative drug will reduce logistical delays and improve access to this treatment for Russian patients.
Russia also recently announced that it will begin clinical trials of the Enteromix cancer vaccine in 2025.
According to Dr. Andrey Kaprin, chief cancer treatment specialist of the Russian Ministry of Health , all Russian citizens are treated for free for all cancers.
Source
Comment (0)